Beneficial effects of lamivudine in hepatitis B virus-related decompensated cirrhosis (Q31431612)

2 July 2017

Beneficial effects of lamivudine in hepatitis B virus-related decompensated cirrhosis (English)

1 reference

ORCID Public Data File 2021

2 July 2017

0 references

1 reference

1 reference

1 reference

1 reference

author name string

Kapoor D

1

1 reference

2 July 2017

Guptan RC

2

1 reference

2 July 2017

Wakil SM

3

1 reference

2 July 2017

Kazim SN

4

1 reference

2 July 2017

Kaul R

5

1 reference

2 July 2017

Agarwal SR

6

1 reference

2 July 2017

Raisuddin S

7

1 reference

2 July 2017

Hasnain SE

8

1 reference

2 July 2017

Sarin SK

9

1 reference

2 July 2017

1 August 2000

1 reference

2 July 2017

Journal of Hepatology

1 reference

2 July 2017

33

1 reference

2 July 2017

2

1 reference

2 July 2017

308-312

1 reference

Effect of Alpha-Interferon Treatment in Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B

2 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980372-4

7 January 2021

Low-dose, titratable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B virus

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980372-4

7 January 2021

Inhibition of the replication of hepatitis B virus in vitro by 2',3'-dideoxy-3'-thiacytidine and related analogues

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980372-4

7 January 2021

A preliminary trial of lamivudine for chronic hepatitis B infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980372-4

7 January 2021

Efficacy of lamivudine in chronic hepatitis B patients with active viral replication and decompensated cirrhosis undergoing liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980372-4

7 January 2021

Evaluation of safety and efficacy of 3TC (lamivudine) in patients with asymptomatic or mildly symptomatic human immunodeficiency virus infection: a phase I/II study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980372-4

7 January 2021

Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980372-4

7 January 2021

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980372-4

7 January 2021

Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980372-4

7 January 2021

A randomized, controlled trial of a 24-month course of interferon alfa 2b in patients with chronic hepatitis B who had hepatitis B virus DNA without hepatitis B e antigen in serum

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980372-4

7 January 2021

Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980372-4

7 January 2021

Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980372-4

7 January 2021

Low-dose recombinant interferon therapy in anti-HBe-positive chronic hepatitis B in Asian Indians

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980372-4

7 January 2021

Hepatitis B virus unable to secrete e antigen and response to interferon in chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980372-4

7 January 2021

Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980372-4

7 January 2021

Extended lamivudine retreatment for chronic hepatitis B: maintenance of viral suppression after discontinuation of therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980372-4

7 January 2021

Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980372-4

7 January 2021

10.1016/S0168-8278(00)80372-4

Identifiers

DOI

1 reference

2 July 2017

1 reference